Abducens nerve schwannoma, Gamma Knife radiosurgery 161, 162
Acetaminophen, anesthesia and sedation 71
Adverse radiation effects, see Radiation necrosis
Afatinib, breast cancer brain metastasis management 131
Age-related macular degeneration (ARMD), Gamma Knife radiosurgery
dosimetry and treatment planning 307, 308
eye fixation techniques 306, 307
outcomes 309, 310
AMP, see Authorized Medical Physicist
Anesthesia, Gamma Knife radiosurgery
Agents
   inhalational 71
   intravenous 70, 71
   muscle relaxants 71
assessment 68, 69
facilities 67
frame-based technique 65, 66
mask-based technique 64, 65
monitoring 70
patient selection 63, 64
pediatric patients 68–70
recovery 71
safety 68
Anorexia nervosa, Gamma Knife radiosurgery 290, 295, 296
ARMD, see Age-related macular degeneration
Arteriovenous fistula, see Dural arteriovenous fistula
Arteriovenous malformation (AVM)
Gamma Knife radiosurgery
   adverse radiation effects 245, 246
   follow-up 240
   grading scales for outcomes 269, 270
   Historical perspective 5, 6, 239, 267, 268
   outcomes 240–242, 268–271
   patient selection 239
   technique 239, 240
   unruptured malformations 245, 270, 271
   volume-staged radiosurgery 243–245
   magnetoencephalography 37, 38
   natural history 268
   overview 238, 239
   stereotactic angiography 31, 32
Astrocytoma, see Glioma
AU, see Authorized user
Authorized Medical Physicist (AMP), roles and training 74–80
Authorized user (AU), roles and training 74–80
AVM, see Arteriovenous malformation
Bevacizumab
- glioblastoma multiforme management with radiosurgery combination 197
- lung cancer brain metastasis management 127, 128
- radiation necrosis management 145, 146
BKM-120, breast cancer brain metastasis management 131

Brain metastasis
- clinical practice
  - overview 125, 126
  - survey 101
- Gamma Knife radiosurgery
  - advantages 102
  - micro-metastasis 104
  - multiple tumors
    - concurrent whole-brain radiation therapy 112
    - cumulative tumor volume versus number of tumors 103, 104
    - dose 104–106
    - Mito Gamma House experience 113–118
    - neurological death 104, 118–121
    - outcomes 111, 112
    - rationale 102
    - safety 114
    - survival factors 118–122
    - University of Pittsburgh guidelines 107, 108
- targeted therapies based on primary tumor
  - breast cancer 130–132
  - lung cancer 126–129
  - melanoma 132–134
- whole-brain radiation therapy
  - limitations 101, 102
  - overview 100, 101
- Breast cancer, targeted therapies for brain metastasis 130–132

Capecitabine, breast cancer brain metastasis management 130, 131

Capsulotomy, Gamma Knife radiosurgery for behavioral disorders 291

Cavernous malformation (CM)
- Gamma Knife radiosurgery
  - cost-benefit analysis 264, 265
  - goals 262
  - historical perspective 261
  - outcomes 263, 264
  - prospects 265
  - technique 262, 263
  - natural history 261
  - overview 260, 261
  - surgical resection 261

Central neurocytoma (CN)
- Gamma Knife radiosurgery
  - adjuvant radiation therapy 235
  - complications 236, 236
  - dosing 235
  - historical perspective 232
  - prognosis 236
  - University of Pittsburgh experience 233, 234
  - overview 232, 233

Chemodectoma, see Glomus tumors

Chondrosarcoma
- Gamma Knife radiosurgery 211–213
  - overview 209
  - surgical resection and fractionated radiotherapy 210, 211

Chordoma
- Gamma Knife radiosurgery 208, 209
  - overview 207
  - surgical resection and fractionated radiotherapy 207, 208

Choroidal metastasis, Gamma Knife radiosurgery
  - outcomes 302–304
  - technique 298–300

CI, see Conformity index

Cingulotomy, Gamma Knife radiosurgery for behavioral disorders 291

Cluster headache, Gamma Knife radiosurgery

CM, see Cavernous malformation

CN, see Central neurocytoma

Cobalt source
  - dose calibration 51, 52
  - leak test 78
  - licensing 74, 75
  - physics 48, 49
  - radiation profiles 51
  - radiation protection 49
  - radiological focal point 51, 54
  - relative output factors 52
  - security 81
  - source distribution within sectors 50

Commissioning, Gamma Knife units 50
Computed tomography (CT)
ICON system 20, 22–26, 31, 52
nursing care on day of surgery 60, 61
pituitary adenoma 151
stereotactic imaging 31
Conformity index (CI) 55, 56
Craniopharyngioma
Gamma Knife radiosurgery
challenges 169–171
outcomes 168, 169
technical considerations 169
University of Pittsburgh experience 167, 168
overview 166, 167
CT, see Computed tomography
Dabrafenib, melanoma brain metastasis management 132, 134, 135
Dacarbazine, melanoma brain metastasis management 133
DAVF, see Dural arteriovenous fistula
Depression, Gamma Knife radiosurgery 290–2945, 296
Dexmedetomidine, anesthesia and sedation 71
Diffusion tensor imaging, see Magnetic resonance imaging
Dural arteriovenous fistula (DAVF)
classification 249
clinical manifestations 250, 251
epidemiology 248
Gamma Knife radiosurgery
complicated fistula management 258
complications 257, 258
follow-up 253
outcomes 251, 254–256
patient selection and evaluation 252
planning 252
technique 252
sites 249
transarterial embolization 251
Ependymoma
epidemiology 200
Gamma Knife radiosurgery 201–203
pathology 201
surgical resection and fractionated radiotherapy 201
Erlotinib, lung cancer brain metastasis management 126–129
Essential tremor (ET), Gamma Knife thalamotomy
benefits 285, 286
imaging changes 283–285
outcomes 281, 282
overview 279, 280
technique 280, 281
ET, see Essential tremor
Exophthalmos, Gamma Knife radiosurgery
dosimetry and treatment planning 307, 308
eye fixation techniques 306, 307
outcomes 312
Facial nerve schwannoma, Gamma Knife radiosurgery 162, 163
FDA, see Food and Drug Administration
Fentanyl, anesthesia and sedation 71
FOCUS precision test 53
Food and Drug Administration (FDA), Gamma Knife regulation 74
Gefitinib, lung cancer brain metastasis management 127, 128
Germ cell tumor, pineal region 174
GI, see Gradient index
Glaucoma, Gamma Knife radiosurgery
dosimetry and treatment planning 307, 308
eye fixation techniques 306, 307
outcomes 308, 309
Glioma
low-grade glioma
Gamma Knife radiosurgery
grade 2 astrocytoma 186–189
pilocytic astrocytoma 185, 186
role 185
overview 184
malignant glioma salvage Gamma Knife radiosurgery
anaplastic glioma 192–194
bevacizumab combination 197
glioblastoma multiforme 194, 195, 197
overview 191, 192
technical considerations 197, 198
University of Pittsburgh experience 195–197
Glomus tumors
Gamma Knife radiosurgery
complications 219, 220
dose selection 217, 220
follow-up 217, 218
outcomes 218, 219
patient selection 216
treatment planning 216, 217, 220
overview 215, 216
Glossopharyngeal neuralgia, Gamma Knife radiosurgery 276
Gradient index (GI) 55, 56

Hemangioblastoma
fractionated radiation therapy 227
Gamma Knife radiosurgery 227, 228, 311
overview 226
surgical resection 226

Hemangioma
Gamma Knife radiosurgery 225, 226
magnetic resonance imaging 223–225

Hemangiopericytoma (HPC)
fractionated radiation therapy 229
Gamma Knife radiosurgery 229, 230
overview 229
surgical resection 229

Historical perspective
Gamma Knife
early history 4, 5
frame-based surgery 21, 22
frameless fixation 23–26
growth 7, 16, 17
pituitary adenoma management 150
regulation 75, 76
University of Pittsburgh 6, 9–16
proton radiosurgery 3, 4
radiosurgery 1–3
X-ray radiosurgery 3
HPC, see Hemangiopericytoma
Hyperbaric oxygen, radiation necrosis management 146

Hypoglossal schwannoma, Gamma Knife radiosurgery 164

ICON
computed tomography 20, 22–26, 31, 52
historical perspective 15, 16
licensing 76
motion management 52, 53
overview of technology 20, 21
prospects 26
IDH, mutation in oligodendroglioma 203
Insurance, Gamma Knife radiosurgery reimbursement 17, 18
Ipilimumab, melanoma brain metastasis management 132–134
Jugular foramen schwannoma, Gamma Knife radiosurgery 163, 164
Ketamine, anesthesia and sedation 70, 71
Ketorolac, anesthesia and sedation 71
Lapatinib, breast cancer brain metastasis management 130, 131
Lung cancer, targeted therapies for brain metastasis 126–129
Magnetic resonance imaging (MRI)
clinical protocols 29–31
contrast agents 31, 34
diffusion tensor imaging 35, 36
hemangioma 223–225
ICON system 22, 23
pituitary adenoma 151
planning for radiosurgery 29
quality assurance 32–34
radiation necrosis diagnosis 142, 143
Magnetic resonance spectroscopy (MRS)
radiation necrosis diagnosis 143
radiosurgery role 34, 35
Magnetoencephalography (MEG), radiosurgery role 37, 38
Medical Event, criteria and reporting 80
Medicare, Gamma Knife radiosurgery reimbursement 17, 18
MEG, see Magnetoencephalography
Melanoma, targeted therapies for brain metastasis 132–134
Meningioma, Gamma Knife radiosurgery
Complications
edema 97
radiation-induced tumors 98
vascular complications 97
hypofractionated radiosurgery for large meningiomas 97
indications 92
outcomes
atypical meningiomas 96
cavernous sinus meningiomas 96
convexity meningiomas 93
malignant meningiomas 96
overview 92, 93
parasagittal/parafalcine meningiomas 93
parasellar meningiomas 95
petroclival meningiomas 96
skull base meningiomas 94, 95
overview 91, 92
recurrent tumor management 96, 97
treatment planning 92
MIB-1 labeling index, central neurocytoma prognosis 236
Midazolam, anesthesia and sedation 70
MRI, see Magnetic resonance imaging
MRS, see Magnetic resonance spectroscopy
Multiple sclerosis-associated trigeminal neuralgia, Gamma Knife radiosurgery 276
Multiple sclerosis-related tremor, Gamma Knife thalamotomy
benefits 285, 286
bilateral thalamotomy 282
imaging changes 283–285
outcomes 282, 283
overview 279, 280
technique 280, 281
Neratinib, breast cancer brain metastasis management 131
Neurofibromatosis type II (NF2), vestibular schwannoma control 84
NF2, see Neurofibromatosis type II
NRC, see Nuclear Regulatory Commission
Nuclear Regulatory Commission (NRC), Gamma Knife regulation 12, 73–75
Nursing care
day of radiosurgery
frame-based radiosurgery 59, 60
imaging 60, 61
mask-based radiosurgery 60
overview 59
discharge an follow-up 61, 62
Gamma Knife procedure instructions 58, 59
postoperative care 61
presurgery evaluation 58
Obsessive-compulsive disorder (OCD), Gamma Knife radiosurgery 289, 290, 292, 293, 295, 296
OCD, see Obsessive-compulsive disorder
Ocular nerve schwannoma, Gamma Knife radiosurgery 160
Olfactory nerve schwannoma, Gamma Knife radiosurgery 159, 160
Oligodendroglioma
epidemiology 203
Gamma Knife radiosurgery 204, 205
pathology 203
surgical resection and fractionated radiotherapy 203, 204
Orbital tumors, Gamma Knife radiosurgery
complications 302–304
metastasis 310
outcomes 300, 301
technique 298–300
Paddick conformity index (PCI) 55, 56
Pallidotomy, see Parkinson’s disease
Parkinson’s disease (PD), Gamma Knife radiosurgery
pallidotomy 286, 287
thalamotomy
benefits 285, 286
imaging changes 283–285
outcomes 282
overview 279, 280
technique 280, 281
PD, see Parkinson’s disease
Pembrolizumab, melanoma brain metastasis management 132, 134
Perfexion, historical perspective 15
PET, see Positron emission tomography
Pilocytic astrocytoma, see Glioma
Pineal region tumors
Gamma Knife radiosurgery
germin cell tumors 174
glioma 178
meningioma 178
metastasis 178
papillary tumors 176–178
parenchymal tumors 174–176
recommendations 178–182
overview 173
Pituitary adenoma
classification 149
Gamma Knife radiosurgery
complications 158, 159
dose selection 151–153
frame and mask placement 151
historical perspective 150
imaging 151
outcomes
adenocorticotropic-secretion adenoma 156
growth hormone-secreting adenoma 155, 156
non-functioning adenoma 153, 154
prolactinoma 153
patient selection 150, 151
planning 151
medical therapy 149, 150
PIV, see Prescribed isodose volume
Plan selectivity (PS) 55, 56
Positron emission tomography (PET)
radiation necrosis diagnosis 143, 144
radiosurgery role 34, 36, 37
Prescribed isodose volume (PIV) 55, 56
Prolactinoma, see Pituitary adenoma
Propofol, anesthesia and sedation 70
PS, see Plan selectivity

QA, see Quality assurance
Quality assurance (QA)
Gamma Knife units 53, 54
magnetic resonance imaging 32–34
registry, see University of Pittsburgh Medical Center Gamma Knife Registry
Radiation necrosis
arteriovenous malformation radiosurgery 245, 246
diagnosis 142–144
epidemiology 139, 130
management
medical treatment 144–146
overview 144
surgical intervention 146, 147
overview of adverse radiation effects 138
pathophysiology 140, 141
pituitary adenoma radiosurgery 158, 159
risk factors 141, 142

Radiation Safety Officer (RSO) 74–78
Radiation safety, Gamma Knife 79
Radiological focal point (RFP) 51, 54
Registry, see University of Pittsburgh Medical Center Gamma Knife Registry
Retinoblastoma, Gamma Knife radiosurgery
dosimetry and treatment planning 307, 308
eye fixation techniques 306, 307
outcomes 310
RFP, see Radiological focal point
Rocuronium, anesthesia and sedation 71
RSO, see Radiation Safety Officer
Schwannoma, see Abducens nerve schwannoma;
Facial nerve schwannoma; Hypoglossal schwannoma; Jugular foramen schwannoma;
Ocular nerve schwannoma; Olfactory nerve schwannoma; Trigeminal nerve schwannoma;
Trochlear nerve schwannoma; Vestibular schwannoma
Sealed Source and Device Registry (SSDR), Gamma Knife approval 74
Sevoflurane, anesthesia and sedation 71
Shielding, radiation 78
Single-photon emission computed tomography (SPECT), radiation necrosis diagnosis 143
SPECT, see Single-photon emission computed tomography
Sphenopalatine neuralgia, Gamma Knife radiosurgery 276
SSDR, see Sealed Source and Device Registry

Target volume (TV) 55, 56
Temozolomide
lung cancer brain metastasis management 127, 129
melanoma brain metastasis management 132
Thalamotomy, see Essential tremor; Multiple sclerosis-related tremor; Parkinson's disease
Thalidomide, melanoma brain metastasis management 132
TN, see Trigeminal neuralgia
Trastuzumab, breast cancer brain metastasis management 130, 131
Treatment planning, Gamma Knife radiosurgery
glomus tumors 216, 217, 220
meningioma 92
overview 54–56
pituitary adenoma 151
Tremor, see Essential tremor; Multiple sclerosis-related tremor; Parkinson’s disease
Trigeminal nerve schwannoma, Gamma Knife radiosurgery 160, 161
Trigeminal neuralgia (TN), Gamma Knife radiosurgery
multiple sclerosis-associated neuralgia 276
outcomes
effectiveness 273, 274
tumor-associated neuralgia 275, 276
predictors of success 274
sensory dysfunction 274, 275
Trochlear nerve schwannoma, Gamma Knife radiosurgery 160
TV, see Target volume

University of Pittsburgh Medical Center Gamma Knife Registry
applications 44–46
data entry 42
design 41, 42
limitations 46
nomenclature 41
prospects 46
quality improvement 42
query functions 44
regulatory oversight 41
requirements 41
role 43
security 42
task force 40, 41

Uveal tumors, Gamma Knife radiosurgery
complications 302–304
metastasis 310
outcomes 301, 302
technique 298–300

Vascular endothelial growth factor (VEGF), radiation necrosis pathophysiology 140
VEGF, see Vascular endothelial growth factor
Vemurafenib, melanoma brain metastasis management 132, 135

Vestibular schwannoma (VS), Gamma Knife radiosurgery
control 83, 84
fractionated stereotactic radiosurgery 85, 86
historical perspective 6
imaging 83
microsurgery 88
outcomes
  facial nerve function 88
  hearing 87
  induced malignancy 88
  trigeminal neuropathy 88
  volumetric outcomes and predictors 84, 85
overview 82, 83
repeat radiosurgery 86, 87
VS, see Vestibular schwannoma

Whole-brain radiation therapy, see Brain metastasis